



Global COVID-19 Clinical Platform

NOVEL CORONAVIRUS (COVID-19) - RAPID VERSION

DESIGN OF THIS CASE RECORD FORM (CRF)

This CRF has 3 modules:

Module 1 to be completed on the first day of admission to the health centre.

Module 2 to be completed on first day of admission to ICU or high dependency unit. Module 2 should also be completed daily for as many days as resources allow. Continue to follow-up patients who transfer between wards.

Module 3 to be completed at discharge or death.

GENERAL GUIDANCE

- The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient is enrolled after the admission date.
- Participant Identification Numbers consist of a site code and a participant number.
 You can obtain a site code and register on the data management system by contacting ncov@isaric.org.
 Participant numbers should be assigned sequentially for each site beginning with 00001. In the case of a single site recruiting participants on different wards, or where it is otherwise difficult to assign sequential numbers, you can assign numbers in blocks or incorporate alpha characters. E.g. Ward X will assign numbers from 00001 or A0001 onwards and Ward Y will assign numbers from 50001 or B0001 onwards. Enter the Participant Identification Number at the top of every page.
- Data are entered to the central electronic REDCap database at https://ncov.medsci.ox.ac.uk or to your site/network's independent database. Printed paper CRFs may be used and the data can be typed into the electronic database afterwards.
- Complete every section. Questions marked "If yes,..." should be left blank when they do not apply (i.e. when the answer is not yes).
- Selections with square boxes (□) are single selection answers (choose one answer only).
- Selections with circular boxes (O) are multiple selection answers (choose all that apply).
- Mark 'Unknown' for any data that are not available or unknown.
- Avoid recording data outside of the dedicated areas.
- If using paper CRFs, we recommend writing clearly in ink, using BLOCK-CAPITAL LETTERS.
- Place an (X) in the boxes to mark the answer. To make corrections, strike through (-----) the data you wish to delete and write the correct data above it. Please initial and date all corrections.
- Please keep all of the sheets for a single participant together e.g. with a staple or participant-unique folder.
- Please transfer all paper CRF data to the electronic database. All paper CRFs can be stored by the institution responsible for them. All data should be transferred to the secure electronic database.
- Please enter data on the electronic data capture system at https://ncov.medsci.ox.ac.uk. If your site would like to collect data independently, we can support the establishment of locally hosted databases.
- Please contact us at ncov@isaric.org. If we can help with databases, if you have comments and to let us know that you are using the forms.





PARTICIPANT ID I	11	11	- 11	- 11		- 11	- 11	- 11	

MODULE1: complete on admission/enrolment

Site name				Country			
Date of enrolment [_D_][_D_]/[_M		_2_][_0)_][_Y_][<u>Y_</u>]			
CLINICAL INCLUSION CRITERI							
Proven or suspected infection with	n pathoge	en of Pu	ublic Hea	alth Interest □Yes □No			
One or more A history	of self-re	eported	l feverish	ness or measured fever of ≥ 3	38₀C □Yes	s □No	
of these Cough					□Yes	s □No	
during this Dyspnoe	ea (shortr	ness of	breath) (OR Tachypnoea*	□Yes	s □No	
illness Clinical	suspicion	of ARI	despite	not meeting criteria above	□Yes	s □No	
* respiratory rate ≥50 breaths/min for	<1 year; ≥	:40 for 1	-4 years;	≥30 for 5-12 years; ≥20 for ≥13 y	rears		
DEMOGRAPHICS							
Sex at Birth □Male □Female	□Not spe	cified	Date of	hirth [D 1[D 1/[M 1[M 1/	/	1 V 1	
If date of birth is unknown, record	•				ʹ┖┈┼┈╢┈┼┈╢┈┼╴	_][⊥]	
Healthcare Worker? □Yes □N					□Unknown		
Pregnant? □Yes □No □Unkr				_		wooks	
Tregnant: Lifes Live Lonki	IOWII LIN		ıı yes.	Oestational weeks assessin		WCCKS	
DATE OF ONSET AND ADMISS	ON VITA	L SIGN	NS (first	available data at presentatior	n/admission)		
Symptom onset (date of first/ear	iest symp	otom) [_	D_][_D	_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]		
Admission date at this facility [D_][_D_]/[_M_]	[_M_]/[_ <i>:</i>	2_][_0_][_Y_][_Y_]			
Temperature [][].[]°C	Heart ra	ate [_][][_]beats/min			
Respiratory rate [][]breat	ns/min						
BP [] [] (systolic) [][][_](diast	tolic) mm	nHg Severe dehydration D	∃Yes □No □	lUnknow	n
Sternal capillary refill time >2se	conds []Yes [⊒No □U	Inknown			
Oxygen saturation: [][]%	6 on □ro	om air [• •	,	circle or	ne)
Glasgow Coma Score (GCS /15)				utrition □Yes □No □Unknov			
Mid-upper arm circumference [][]	[]mı	m H	eight: [] [] []cm	Weight: [][][_]kg
CO-MORBIDITIES (existing prior	to admis:	sion) (L	Jnk = Un	known)			
Chronic cardiac disease (not hypertension)	□Yes	□No	□Unk	Diabetes	□Yes	□No	□Unk
Hypertension	□Yes	□No	□Unk	Current smoking	□Yes	□No	□Unk
Chronic pulmonary disease	□Yes	□No	□Unk	Tuberculosis	□Yes	□No	□Unk
Asthma	□Yes	□No	□Unk	Asplenia	□Yes	□No	□Unk
Chronic kidney disease	□Yes	□No	□Unk	Malignant neoplasm	□Yes	□No	□Unk
Chronic liver disease	□Yes	□No	□Unk	Other	□Yes	□No	□Unk
Chronic neurological disorder	□Yes	□No	□Unk	If yes, specify:			
HIV	□Yes-c	n ART	□Yes	s-not on ART □No □Ui	nknown		
PRE-ADMISSION & CHRONIC N	IEDICAT	ION	Were a	any of the following taken w	ithin 14 days o	of admi	ssion?
Angiotensin converting enzyme in	hibitors (ACE inl	hibitors)?	? □Yes □No □Unknown			
Angiotensin II receptor blockers (A	ARBs)?			□Yes □No □Unknown			
Non-steroidal anti-inflammatory (N	ISAID)?			□Yes □No □Unknown			





Organization ISARIC			PARTI	CIPANT ID II II I	_	_11	
SIGNS AND SYMPTON	MS ON ADMISS	ION (Unk = Unki	nown)			
History of fever	□Yes	□No	□Unk	Lower chest wall indrawing	□Yes	□No	□Unk
Cough	□Yes	□No		Headache.	□Yes	□No	□Unk
with sputum produc	tion □Yes	□No	□Unk	Altered consciousness/conf	usion □Yes	□No	□Unk
with haemoptysis	□Yes	□No	□Unk	Seizures	□Yes	□No	□Unk
Sore throat	□Yes	□No	□Unk	Abdominal pain	□Yes	□No	□Unk
Runny nose (rhinorrhoea)	. □Yes	□No		Vomiting / Nausea	□Yes	□No	□Unk
Wheezing	□Yes	□No	□Unk	Diarrhoea	□Yes	□No	□Unk
Chest pain.	□Yes	□No	□Unk	Conjunctivitis	□Yes	□No	□Unk
Muscle aches (myalgia)	□Yes	□No	□Unk	Skin rash	□Yes	□No	□Unk
Joint pain (arthralgia).	□Yes	□No	□Unk	Skin ulcers	□Yes	□No	□Unk
Fatigue / Malaise	□Yes	□No	□Unk	Lymphadenopathy	□Yes	□No	□Unk
Shortness of breath .	□Yes	□No	□Unk	Bleeding (Haemorrhage).	□Yes	□No	□Unk
Inability to walk	□Yes	□No	□Unk	If bleeding: specify site(s):			
Other □Yes □No □Un	k If yes, specify:		,	y , , , ,			
MEDICATION Is the			receiving	any of the following?			
Antiviral? □Yes □No OInterferon alpha OInt Corticosteroid? □Yes If yes, please provide Antibiotic? □Yes □N Antimalarial agent? □ Experimental agent? Non-steroidal anti-infla Angiotensin convertin Angiotensin II recepto SUPPORTIVE CARE ICU or High Dependen Oxygen therapy? □Yes O2 flow: □1-5 L Source of oxygen	□Unknown If terferon beta O s □No □Unknown e agent and max o □Unknown □Yes □No □Un □Yes □No □Un ammatory (NSA g enzyme inhib r blockers (ARI Is the patient cy Unit admiss es □No □ Un Jmin □6-10 L/n gen: □Piped □ sal prongs □HI on? (e.g.BIPAP)	yes: 0 Other, wn I common like the second like	ORibavirin specify:f yes, route daily dose: If yes, so If yes, so If yes □No □ ENTLY rec □Yes □No If yes, con If yes □No If yes, con If yes □No If yes □No If yes □No If yes, con If yes, con If yes □No If yes □N	Antifungal a pecify:	Neuraminidase inh OInhaled agent? □Yes □N known ring?	No □Ur	□Unknown
Extracorporeal (ECMO	<u> </u>			-	? □Yes □No □	Unknow	'n
LABORATORY RESUL	TS ON ADMIS	SION (*record uni	ts if different from those l	isted)		
Parameter	Value*		Not done	Parameter	Value*		Not done
Haemoglobin (g/L)				Creatinine (µmol/L)			
WBC count (x10 ₉ /L)				Sodium (mEq/L)			
Haematocrit (%)				Potassium (mEq/L)			
Platelets (x10 ₉ /L)				Procalcitonin (ng/mL)			
APTT/APTR				CRP (mg/L)			
PT (seconds)				LDH (U/L)			
INR				Creatine kinase (U/L)			
ALT/SGPT (U/L)				Troponin (ng/mL)			
Total bilirubin (µmol/L)				ESR (mm/hr)			
AST/SGOT (U/L)				D-dimer (mg/L)			
Urea (BUN) (mmol/L)				Ferritin (ng/mL)			
Lactate (mmol/L)				IL-6 (pg/mL)			





PARTICIPANT ID I	- 11	- 11	- 11	- 11	l l	- 11	- 11	- 11	

MODULE 2: follow-up (frequency of completion determined by available resources)

Date of follow up [_D_][
VITAL SIGNS (record r							• .			
Temperature [][]	-	-				- '	-		-	
BP [] [] (sys									□Unkr	nown
Sternal capillary refill							/15 [][_	-		
Oxygen saturation [air □ ox	ygen therapy □Unknov	vn	A V P	U (circ	cle one)
DAILY CLINICAL FEAT	TUR	· ·	= Unkn					T		
Cough		□Yes	□No	□Ur		Seizures		□Yes	□No	□Unk
and sputum producti Sore throat	on	□Yes □Yes	□No □No	□Ur □Ur		/omiting / Nausea Diarrhoea		□Yes □Yes	□No □No	□Unk □Unk
Chest pain		□Yes	□No	□Ur		Conjunctivitis		□Yes	□No	□Unk
Shortness of breath		□Yes	□No	□Ur		Myalgia		□Yes	□No	□Unk
Confusion		□Yes	□No	□Ur		Other, specify:		□Yes	□No	□Unk
LABORATORY RESUL	.TS (*record u	ınits if d	lifferer		those listed)				
Parameter	Val	ue*			Not done	Parameter	Value*			Not done
Haemoglobin (g/L)						Creatinine (µmol/L)				
WBC count (x109/L)						Sodium (mEq/L)				
Haematocrit (%)						Potassium (mEq/L)				
Platelets (x10 ₉ /L)						Procalcitonin (ng/mL)				
APTT/APTR						CRP (mg/L)				
PT (seconds)						LDH (U/L)				
INR						Creatine kinase (U/L)				
ALT/SGPT (U/L)						Troponin (ng/mL)				
Total bilirubin (µmol/L)						ESR (mm/hr)				
AST/SGOT (U/L)						D-dimer (mg/L)				
Urea (BUN) (mmol/L)						Ferritin (ng/mL)				
Lactate (mmol/L)						IL-6 (pg/mL)				
MEDICATION Is the										
Oral/orogastric fluids?										
Antiviral? □Yes □No			-			•	leuraminid	ase inhibi	tor	
OInterferon alpha OInt					-					
Corticosteroid? □Yes										
			naximur	n daily						
Antibiotic? □Yes □N						tifungal agent? □Yes		nknown		
Antimalarial agent?										
Experimental agent?						•				
Non-steroidal anti-infla		• •	•							
Angiotensin convertin	•	•		•		•	ıknown			
Angiotensin II receptor										
SUPPORTIVE CARE							ving?			
ICU or High Dependen	-									
Oxygen therapy?				-		•				
						/min □>15 L/min □Ur	ıknown			
Source of oxygen:		•	•							
Interface: □Nasal prongs □HF nasal cannula □Mask □Mask with reservoir □CPAP/NIV mask □Unknown										
Non-invasive ventilation? (e.g. BIPAP, CPAP)										
· ·	Invasive ventilation (Any)? □Yes □No □Unknown Inotropes/vasopressors? □Yes □No □Unknown									
Extracorporeal (ECMO	-	-					position?	P□Yes □	⊒No □] Unknown
Renal replacement the	rapy	(RRT) o	r dialys	is? [∃Yes [□No □Unknown				





PARTICIPANT ID I	1.1	1.1	- 1.1	- 1.1	I I	1.1	- 1.1	1.1	- 1
FAITICIFAITIDI	11	1.1	1.1	11	1 1	1.1	11	1.1	

MODULE 3: complete at discharge/death

DIAGNOSTIC/PATHOGEN TI	ESTING					
Chest X-Ray /CT performed? □Yes □No □Unknown If Yes: infiltrates present? □Yes □No □Unknown						
Was pathogen testing done	during this illness episode? \Box	⊒Yes □No □Unknown If	yes, complete all below:			
Influenza virus: □Positive	e □Negative □Not done If posit	ive, type				
Coronavirus: □Positive □	Negative □Not done If positive	e: □MERS-CoV □SARS-C	CoV-2 □Other			
Other respiratory pathoge	en: □Positive □Negative □Not o	done If positive , specify _				
Viral haemorrhagic fever:	: □Positive □Negative □Not don	ne If positive, specify virus	S			
Other pathogen of public	health interest detected: If ye	es, specify:				
	sitive □Negative □Not done Nor					
HIV: □Positive □Negative			3			
COMPLICATIONS: At any tim	ne during hospitalisation did t	he patient experience:				
Shock	□Yes □No □Unknown	Bacteraemia	□Yes □No □Unknown			
Seizure	□Yes □No □Unknown	Bleeding	□Yes □No □Unknown			
Meningitis/Encephalitis	□Yes □No □Unknown	Endocarditis	□Yes □No □Unknown			
Anaemia	□Yes □No □Unknown	Myocarditis/Pericarditis	□Yes □No □Unknown			
Cardiac arrhythmia	□Yes □No □Unknown	Acute renal injury	□Yes □No □Unknown			
Cardiac arrest	□Yes □No □Unknown	Pancreatitis	□Yes □No □Unknown			
Pneumonia	□Yes □No □Unknown	Liver dysfunction	□Yes □No □Unknown			
Bronchiolitis	□Yes □No □Unknown	Cardiomyopathy	□Yes □No □Unknown			
Acute Respiratory Distress Syndrome	□Yes □No □Unknown	Other If Yes, specify	☐Yes ☐No ☐Unknown			
	lised or at discharge, were any		torod?			
	S □No □Unknown Intravenou					
_						
	known If yes: ORibavirin OLo	- -				
	OInterferon beta OOther, specinknown If yes, specify:					
			_1			
	Unknown If yes, route: OO		u			
	aximum daily dose:					
	No □Unknown If yes, specify:					
Antimalarial agent? □Yes [□No □Unknown If yes, specif	ⁱ y:				
Experimental agent? □Yes	□No □Unknown If yes, spec	cify:	_			
	t ory (NSAID) □Yes □No □U					
SUPPORTIVE CARE: At ANY	' time during hospitalisation, c	did the patient receive/und	lergo:			
ICU or High Dependency Uni	it admission? □Yes □No □	Unknown If yes, total dur	ration:days			
Date of ICU admissi	ion:[_D_][_D_]/[_M_][_M_]/[_2_]		•			
	ge:[_D_][_D_]/[_M_][_M_]/[_2_][t outcome IDN/A			
	ye.[_b_][_b_]/[_m_][_m_]/[_b] No □Unknown If yes, comple					
			:days			
	min O 6-10 L/min O 11-15 L/min					
	ed OCylinder OConcentrator		ND A D (AU) (
. •	s OHF nasal cannula OMask					
Non-invasive ventilation? (e.	.g. BIPAP, CPAP) □Yes □No	☐ Unknown If yes, total d	luration:days			
Invasive ventilation (Any)? □	lYes □No □Unknown If yes	, total duration:c	days			
Extracorporeal (ECMO) supp	oort? Yes No Unknown	If yes, total duration:	days			
Prone position? □Yes □No	□ Unknown If yes, total dura	ition: days	•			
-	RRT) or dialysis? □Yes □No	-				
-	res □No □Unknown If yes ,		ays			
OUTCOME						
	☐Hospitalized ☐Transfer to ot	her facility. □Death. □Pallia	ative discharge. □Unknown			
· ·	M_][_M_]/[_2_][_0_][_Y_][_Y_]	•	3 discharge Dominiowii			
			oo boforo illnoco 🖂Ware -			
וו טואכוומוged allve: Ability t	o self-care at discharge versu		as defore iliness ∟vvorse r □Unknown			





COVID-19 CASE REPORT FORM RAPID CRITICAL CARE MODULE

This is an optional form to be completed together with the **RAPID CRF** for patients receiving critical care on whom the data below are available.

RAPID COVID-19 CRF users:

- Complete this form for patients receiving critical care in any ward, in addition to the RAPID COVID-19 CRF.
- Sites should select whether they complete Part A only or both Parts A & B depending on the availability of data and resources.
- The selected parts of this form (A only or A&B) should be completed in addition to the RAPID Module 2
 (Daily Form) both:
 - on the day of admission to an intensive care / high dependency unit or on the first day of deterioration to severe disease in any ward
 AND
 - 2) each day that the patient is receiving critical care (depending on resource availability).
- Complete the RAPID CRF as per the RAPID CRF guidance.
- Please note, as indicated on the form, that the top section of Part B is to be completed only once (on the first day of admission to ICU or deterioration to severe disease).





PARTICIPANT IDENTIFICATION #: [__][__][__]-- [__][__][__]

PART A

ADMISSION AND DAILY IN ICU/HDU
DATE OF ASSESSMENT (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]
Current admission to ICU or other High Dependency Unit (HDU)? □YES −ICU □ Yes -HDU □NO □Unknown
Is the patient currently receiving, or has received (between 00:00 to 24:00 on day of assessment)
Any vasopressor/inotropic support? □YES □NO □Unknown
If YES, what was the highest level of support received on the date of assessment?
□Dopamine <5µg/kg/min OR Dobutamine OR milrinone OR levosimendan
□Dopamine 5-15μg/kg/min OR Epinephrine/Norepinephrine < 0.1μg/kg/min OR vasopressin OR phenylephrine
□Dopamine >15μg/kg/min OR Epinephrine/Norepinephrine > 0.1μg/kg/min
□Unknown
Prone positioning? □YES □NO □Unknown
Neuromuscular blocking agents? □YES □NO □Unknown Inhaled Nitric Oxide? □YES □NO □Unknown
Tracheostomy inserted? □YES □NO □Unknown Dialysis/Hemofiltration? □YES □NO □Unknown
Other intervention or procedure not already recorded in this form or in the RAPID Module 2 form:
□YES □NO □Unknown If YES, specify:
Record the values associated with the 'worst' blood gas analysis on the day of assessment. 'Worst' is defined as the blood gas with the lowest PaO2/FiO2 ratio.
Any supplemental oxygen (record the highest level of support on day of assessment):
FiO ₂ (0.21-1.0) [].[] or [][] % or [][]L/min
PaO₂ (at time nearest to the FiO₂ above) [][] □ kPa or □ mmHg □ Not done
PaO₂ sample type: □Arterial □Capillary □Unknown
From same blood gas record as PaO₂:
PCO ₂ □ kPa or □ mmHg pH HCO ₃ mEq/L Base excess mmol/L
Richmond Agitation-Sedation Scale (RASS) [] or Riker Sedation-Agitation Scale (SAS) [] Unknown
Most abnormal mean arterial blood pressure [][]mmHg □Unknown
Urine flow rate IF patient age >18 years [][][][]mL/24 hours □Check if estimated □Unknown
IF patient age <18 years [][][][]mL/kg/24hrs □Check if estimated □Unknown





PARTICIPANT IDENTIFICATION #: [__][__][__]-- [__][__][__]

PART B

2
ICU/HDU ADMISSION FORM (complete on first day of ICU/HDU admission only)
ICU ADMISSION DATE (DD/MM/YYYY): [_D_][_D_]/[_M_][_M_]/[_2_][0_][_Y_][_Y_]
Enrolment in interventional clinical study? YES NO Unknown If YES, name of study: or
Treatment/s trialled:
Unknown
Reason for ICU admission (tick all that apply): ORespiratory failure OSeptic shock OVenous thromboembolism
OCardiovascular complications OAcute kidney injury OAcute liver injury ONeurological complications OSecondary infection
OPancreatic injury ODisseminated intravascular coagulation OPregnancy related complications ORhabdomyolysis
OOTHER (please specify)
Clinical Frailty Score (CFS/9) []
DAILY FORM (Complete daily for duration of ICU/ITU/IMC/HDU admission) (between 00:00 to 24:00 on day of assessment) Record the 'worst' value on the day of assessment.
IF patient is <18 years: PELOD Total Score [] □ Unknown PRISM III score: [] □ Unknown
Fluid balance (in last 24 hours) (mL) □Unknown
Nutrition ☐ Parenteral ☐ Enteral ☐ NPO ☐ Unknown Best physical mobility []/10 (see scoring below) ☐ Unknown
 Passively moved by staff (incl. passive cycling only) Any activity in bed, but not moving out of or over edge of bed (incl. cycling) Passively moved to chair (no standing or sitting at edge of bed) Actively sitting over side of bed with some trunk control (may be assisted) Valking with assistance of 2 or more people (>5m) Walking with assistance of 1 person (>5m) Walking independently with gait aid (>5m) Transferring from bed to chair
Is the patient currently receiving (between 00:00 to 24:00 on day of assessment):
Invasive ventilation? ☐YES ☐NO ☐Unknown If YES: OETT OTracheostomy OOTHER (please specify) ☐Unknown
Non-invasive ventilation? ☐YES ☐NO ☐Unknown If YES: ○BIPAP ○CPAP ○OTHER (please specify)☐Unknown
Humidified high flow nasal cannula (HHFNC)? □YES □NO □Unknown
If mechanically ventilated: Mode of ventilation (specify): □Volume Controlled (VC) □Pressure Controlled (PC)
☐ Other(drop down): ☐Unknown
Highest Tidal volume within last 24hrs (ml/Kg of Ideal Body Weight): Unknown
Highest Positive end expiratory pressure within last 24hrs (cmH2O): □Unknown
righest Positive end expiratory pressure within last 24ms (time20).
Highest Airway plateau pressure within last 24 hrs (cmH2O):
Highest Airway plateau pressure within last 24 hrs (cmH2O): Unknown
Highest Airway plateau pressure within last 24 hrs (cmH2O): □Unknown Prone positioning? □YES □NO If YES, total durationhours spent □Unknown
Highest Airway plateau pressure within last 24 hrs (cmH2O): □Unknown Prone positioning? □YES □NO If YES, total durationhours spent □Unknown Sedation? □YES □NO □Unknown If YES: OBenzodiazepines OPropofol ONarcotics
Highest Airway plateau pressure within last 24 hrs (cmH2O): □Unknown Prone positioning? □YES □NO If YES, total durationhours spent □Unknown Sedation? □YES □NO □Unknown If YES: OBenzodiazepines OPropofol ONarcotics OOther (please specify) □Unknown
Highest Airway plateau pressure within last 24 hrs (cmH2O):
Highest Airway plateau pressure within last 24 hrs (cmH2O):
Highest Airway plateau pressure within last 24 hrs (cmH2O):
Highest Airway plateau pressure within last 24 hrs (cmH2O):
Highest Airway plateau pressure within last 24 hrs (cmH2O):